Vivos Therapeutics reports Q3 revenue growth, regains Nasdaq compliance
Vivos Therapeutics (VVOS) reported Q3 2026 revenue of $6.4M, up 24% from Q2 2026. Operating loss improved 18% YoY to $3.9M. Nine-month revenue rose 23% to $16.7M. Gross margin was 52% in Q3. Net loss was $2.0M, improved from $5.4M in Q3 2025. Cash fell to $0.2M. Nasdaq compliance regained.
How this was made
The 30-second read
Why it matters
The quarter shows revenue growth and cost reductions, while Nasdaq compliance reduces a key technical overhang. However, liquidity is extremely tight and gross margin declined due to lower product revenue, which may drive skepticism about sustainability.
Market read
Traders may reprice VVOS on reduced listing-risk and improved operating trajectory, while monitoring cash runway and margin quality for follow-through.
What to watch
The $2.9M other income from Employee Retention Credit reversal can mask underlying operating momentum; investors may focus on recurring gross margin and cash burn rather than headline net loss improvement.
Background
Vivos Therapeutics is a medical device company focused on sleep apnea treatment, with recent strategy described as shifting away from appliance sales to dentists.
Ticker impact
Vivos reported Q3 revenue of $6.4M (+24% QoQ), improved operating loss, and said Nasdaq compliance was regained via the equity requirement.
Likely modest upside bias as compliance risk fades, tempered by liquidity concerns and gross margin pressure.
The article combines a fresh quarterly operating update with a specific Nasdaq compliance milestone, but also highlights cash at $0.2M and gross margin down vs prior year.
Market effects
Sleep-apnea medical device peers may see marginal sentiment lift for the category if Vivos’ cost actions and dentist-channel shift show traction.
Limited, company-specific impact likely confined to small-cap healthcare sentiment.
Low, no cross-border operational or regulatory linkage described.
Counterpoint
The Nasdaq compliance win may not offset balance-sheet fragility, since cash is only $0.2M and gross margin fell year over year.
Key entities
- companyVivos Therapeutics Inc.
Reported Q3 revenue growth, improved operating loss, and regained Nasdaq minimum stockholders’ equity compliance.
- exchangeNasdaq
Notified Vivos it regained compliance with the minimum stockholders’ equity requirement, subject to monitoring.

